Multicenter Clinical Evaluation of Etest Meropenem-Vaborbactam (bioMérieux) for Susceptibility Testing of Enterobacterales (Enterobacteriaceae) and Pseudomonas aeruginosa

Meropenem-vaborbactam (MEV) is a novel carbapenem–beta-lactamase inhibitor combination antibiotic approved by the U.S. Food and Drug Administration (FDA) for treatment of complicated urinary tract infections, including pyelonephritis, in adults. In this study, we evaluated the performance of Etest M...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Microbiol
Prif Awduron: Jean, Sophonie, Garrett, Sheri, Anglade, Claire, Bridon, Laurence, Davies, Leanne, Garner, Omai B., Richards, Jennifer, Wallace, Meghan, Wootton, Mandy, Burnham, Carey-Ann D.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society for Microbiology 2019
Pynciau:
Bacteriology
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6935911/
https://ncbi.nlm.nih.gov/pubmed/31619532
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JCM.01205-19
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg